A185750 Stock Overview
Engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Chong Kun Dang Pharmaceutical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩100,400.00 |
| 52 Week High | ₩136,500.00 |
| 52 Week Low | ₩69,428.57 |
| Beta | 0.90 |
| 11 Month Change | -1.38% |
| 3 Month Change | -7.89% |
| 1 Year Change | 25.65% |
| 33 Year Change | -12.61% |
| 5 Year Change | 36.32% |
| Change since IPO | 96.21% |
Recent News & Updates
Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12
Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Apr 09Recent updates
Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Apr 09Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Apr 19Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock
Apr 05Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?
Mar 09Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Feb 24The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It
Feb 11Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?
Jan 27
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Jan 12With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting
Dec 28What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?
Dec 09Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?
Nov 24Shareholder Returns
| A185750 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.6% | 0.8% | 2.0% |
| 1Y | 25.6% | 7.5% | 6.7% |
Return vs Industry: A185750 exceeded the KR Pharmaceuticals industry which returned 5.6% over the past year.
Return vs Market: A185750 exceeded the KR Market which returned 4.5% over the past year.
Price Volatility
| A185750 volatility | |
|---|---|
| A185750 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.3% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A185750 has not had significant price volatility in the past 3 months.
Volatility Over Time: A185750's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 2,291 | Young-Joo Kim | www.ckdpharm.com |
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. It provides prescription drugs for anticancer, anti-hypertension, anti-hyperlipidemia, anti-diabetic, and immunosuppressant products; over-the-counter drugs for therapeutic benefits, supplements, and other preventive products; health supplements with preventive benefits, including prebiotics and vitamins with Omega-3; and consumer health products, such as red-ginseng healthy drink, hand sanitizer, and hair color medication, as well as insecticides. The company also exports its products.
Chong Kun Dang Pharmaceutical Corp. Fundamentals Summary
| A185750 fundamental statistics | |
|---|---|
| Market cap | ₩1.28t |
| Earnings (TTM) | ₩202.24b |
| Revenue (TTM) | ₩1.67t |
6.3x
P/E Ratio0.8x
P/S RatioIs A185750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A185750 income statement (TTM) | |
|---|---|
| Revenue | ₩1.67t |
| Cost of Revenue | ₩1.01t |
| Gross Profit | ₩659.25b |
| Other Expenses | ₩457.01b |
| Earnings | ₩202.24b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.87k |
| Gross Margin | 39.58% |
| Net Profit Margin | 12.14% |
| Debt/Equity Ratio | 25.4% |
How did A185750 perform over the long term?
See historical performance and comparison